EN DE

Golden House Ltd (GOHO) Fair Value & Analysis

Healthcare · Il · Market cap 166M ILA

GH Golden House Ltd GOHO · TA
Price10.67 ILA
Fair Value10.58 ILA
Upside-0.8%
Quality64/100
Watch Golden House Ltd for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Loss-making · -14.2% net margin
Low debt · generates free cash flow
1.17% dividend yield
Mixed vs. peers (6/13)
Narrow moat 35/100
Evidence: High Range 8.72 ILA – 10.58 ILA Share as image

Fair value as of: Jul 12, 2026

From 24 valuation models · updated 28 days ago

Share price −3.2% over the past month.

A solid business, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Our model range runs from 8.72 ILA (bear) to 10.58 ILA (bull), base 10.58 ILA. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 64/100 (solid quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

29.15 ILA 7.95 ILA Fair Value 10.58 ILA Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

60‑month range 7.95 ILA – 29.15 ILA · fair‑value band 8.72 ILA – 10.58 ILA · the 10.67 ILA price screens above the 10.58 ILA fair value. Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Golden House Ltd (GOHO) currently trades at 10.67 ILA, while our model-based Fair Value estimate is 10.58 ILA, implying the stock looks roughly 0.8% fairly valued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Golden House Ltd generated revenue of 46.0M ILA at a net margin of -14.2%. Revenue grew 18.2% year over year. It earns a return on equity of -2.1%. The balance sheet holds a net cash position of 18.1M ILA. Fundamentals as of Jul 12, 2026

Our scenario range runs from 8.72 ILA (bear case) to 10.58 ILA (bull case); at 10.67 ILA, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -1%, GOHO screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 9.49 ILA 10.60 ILA 12.27 ILA 80
Residual Income 11.40 ILA 10.84 ILA 7.98 ILA 76
Rev-Margin DCF 8.57 ILA 10.15 ILA 12.13 ILA 74
All 24 models by family
DCF Models
FCF DCF 9.39 ILA 10.58 ILA 12.49 ILA 38
Owner Earnings 7.46 ILA 8.20 ILA 9.38 ILA 31
5Y Revenue Exit 8.57 ILA 10.03 ILA 12.11 ILA 39
5Y EBITDA Exit 8.99 ILA 10.74 ILA 13.02 ILA 41
5Y P/E Exit 10.26 ILA 12.92 ILA 16.02 ILA 38
10Y Revenue Exit 8.84 ILA 10.05 ILA 11.38 ILA 36
10Y EBITDA Exit 9.14 ILA 10.45 ILA 11.90 ILA 37
10Y P/E Exit 9.81 ILA 11.68 ILA 13.60 ILA 35
Earnings-Based
Graham-Dodd 3.18 ILA 5.58 ILA 6.84 ILA 54
EPV 7.02 ILA 7.35 ILA 7.61 ILA 59
Dividend Discount
Gordon GGM 87.54 ILA 105.25 ILA 121.30 ILA 70
DDM Multi-Stage 87.54 ILA 109.10 ILA 130.84 ILA 61
Multiples
P/E Multiple 7.73 ILA 10.30 ILA 12.88 ILA 63
P/S Multiple 5.97 ILA 7.96 ILA 9.95 ILA 58
P/B Multiple 5.97 ILA 7.96 ILA 9.95 ILA 55
EV/EBIT 9.66 ILA 11.43 ILA 13.20 ILA 53
EV/EBITDA 9.31 ILA 10.97 ILA 12.62 ILA 54
EV/Revenue 8.14 ILA 9.76 ILA 11.39 ILA 43
Asset-Based
NCAV (Graham) 8.72 ILA 11.69 ILA 17.45 ILA 50
Growth DCF
Growth DCF 9.49 ILA 10.60 ILA 12.27 ILA 80
Rev-Margin DCF 8.57 ILA 10.15 ILA 12.13 ILA 74
Economic Profit
Residual Income 11.40 ILA 10.84 ILA 7.98 ILA 76
ROIC Compounder 7.02 ILA 7.35 ILA 7.61 ILA 72
Growth Earnings
Growth-Adj P/E 5.45 ILA 7.78 ILA 10.12 ILA 68

Widest divergence: Dividend Discount (105.25 ILA) versus Earnings-Based (5.58 ILA). Highest evidence: Growth DCF (80).

Notify me when GOHO reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 46.0M ILA
Revenue growth (YoY) +18.2%
Net margin -14.2%
Return on equity -2.1%
Free cash flow 10.4M ILA FY2025
P/E ratio 24.2
More key figures
Operating margin 22.8%
EPS (TTM) 0.4400 ILA
Dividend yield 1.2%
EPS growth (YoY) -17.4%
Net cash 18.1M ILA FY2025

Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 63 · Market factors (momentum, volatility) 39

Profitability 25
Margins and returns on capital today
Quality Growth 46
Are margins and returns improving?
Cashflow 84
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 74
Calm price path (market factor)
Momentum 30
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Golden House Ltd engages in the operation and management of sheltered housing centers for the elderly population in Israel. It operates The Golden Age House, that contains housing units, as well as public areas, a lobby, a clubhouse, a library, cinema hall, computer room, synagogue, classrooms, lecture rooms, gym, and green garden terrace.

Full company description

Golden House Ltd engages in the operation and management of sheltered housing centers for the elderly population in Israel. It operates The Golden Age House, that contains housing units, as well as public areas, a lobby, a clubhouse, a library, cinema hall, computer room, synagogue, classrooms, lecture rooms, gym, and green garden terrace. The company also offers nursing care services. In addition, it is involved in the renting of commercial buildings. The company was incorporated in 1982 and is headquartered in Tel Aviv-Yafo, Israel.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Golden House Ltd reported revenue of 48.9M ILA in FY2025 versus 56.2M ILA in FY2021, a compound −3.4%/yr. Reported net income was 7.3M ILA in FY2025, compounding −11.3%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
48.9M ILS
Latest YoY
+22.7%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−7.9%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−4.0%
Avg. growth/yr (18Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+2.8%
Revenue −3.4%/yr
FY21 56.2M ILA
FY22 62.5M ILA
FY23 61.1M ILA
FY24 39.8M ILA
FY25 48.9M ILA
Net income −11.3%/yr
FY21 11.7M ILA
FY22 83.7M ILA
FY23 16.1M ILA
FY24 116M ILA
FY25 7.3M ILA
Character of growth · EPS growth decomposed (2014-2025) +14.1 % p.a.
Revenue per share −2.1 pp

of which total revenue −0.9 pp · buybacks/dilution −1.2 pp

EBIT margin −10.0 pp
Tax rate −0.4 pp
Residual (interest, one-offs) +26.5 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch GOHO: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Golden House Ltd Fair Value". https://www.fairvalue-calculator.com/stock/GOHO

Peer Group

Medical Care Facilities · 261 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Top 25%
Fair Value upside −1% · Above median
Return on assets 0% · Bottom 25%
Net margin (TTM) -14% · Bottom 25%
Operating margin (TTM) 23% · Top 25%
Revenue growth 18% · Top 25%
Dividend yield (TTM) 1.2% · Below median
Debt / equity 0.05× · Lower than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/E (TTM) 24.3× · Pricier than median
P/B 0.20× · Cheaper than 75% of peers
P/S (TTM) 1.18× · Pricier than median
P/FCF 5.2× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 32 · sector 23
FUTURE 91 · sector 24
PAST 0 · sector 30
HEALTH 97 · sector 90
DIVIDEND 23 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare Golden House Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Golden House Ltd (GOHO) overvalued or undervalued?
As of Jul 12, 2026, our model estimates a fair value of 10.58 ILA versus a price of 10.67 ILA, about −1% (fairly valued).
What is the fair value of GOHO?
Our model-based fair value for Golden House Ltd is 10.58 ILA (as of Jul 12, 2026), built from audited fundamentals. The current price is 10.67 ILA.
What is the quality score of GOHO?
Golden House Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Golden House Ltd (GOHO)?
Golden House Ltd reported trailing-twelve-month revenue of about 46.0M ILS (latest available figure, as of Jul 12, 2026).
What is the net profit margin of GOHO?
The net profit margin of Golden House Ltd is about -14.2%, meaning it is currently running at a net loss. Based on the latest reported figures.
Does Golden House Ltd pay a dividend?
Golden House Ltd currently shows a dividend yield of about 1.17% relative to its recent price (as of Jul 12, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Golden House Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.